Skip to main
CBLL

Ceribell Inc (CBLL) Stock Forecast & Price Target

Ceribell Inc (CBLL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CeriBell is showing strong potential for growth in the near future, with a significant increase in usage expected for their delirium monitoring product following FDA clearance. The company has a wide range of hospital settings where their products are being used, and the addition of a pediatric/neonate offering is expected to further expand their revenue. With a clean execution, strong financials, and a healthy business model, CeriBell is a solid investment option for the future.

Bears say

CeriBell is poised for growth with a strong market position in point-of-care rapid EEG and plans for label expansions. However, potential risks such as geopolitical tensions, competition, and regulatory decisions could impact its growth potential. The company has also recently received FDA 510(k) approval for two new AI algorithm enhancements and announced the development of a new hardware platform, potentially increasing its appeal and market share. While the stock may have near-term volatility, the company's long-term outlook is positive, with an expected increase in account adds and overall utilization.

Ceribell Inc (CBLL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ceribell Inc (CBLL) Forecast

Analysts have given Ceribell Inc (CBLL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Ceribell Inc (CBLL) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ceribell Inc (CBLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.